Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers

被引：0
|
作者：
Payne, Susan [1 ]
Depke, Mitchell [1 ]
Yueh, Alex [1 ]
Sharick, Joseph T. [2 ]
Favreau, Peter F. [2 ]
Pasch, Cheri A. [1 ]
Clipson, Linda [1 ]
Matkowskyj, Kristina A. [1 ]
Skala, Melissa [2 ]
Deming, Dustin A. [1 ]
机构：
[1] Univ Wisconsin, Madison, WI USA
[2] Morgridge Inst Res, Madison, WI USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3472
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
    Park, Ye-Lim
    Kim, Hwang-Phill
    Cho, Young-Won
    Min, Dong-Wook
    Cheon, Seul-Ki
    Lim, Yoo Joo
    Song, Sang-Hyun
    Kim, Sung Jin
    Han, Sae-Won
    Park, Kyu Joo
    Kim, Tae-You
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (02) : 389 - 401
  • [32] Unilateral focal palmoplantar keratoderma associated with a postzygotic variant in PIK3CA and activation of the PI3K/AKT/mTOR pathway
    Gong, Zhuoqing
    Peng, Sha
    Wang, Huijun
    Jiang, Xingyuan
    Ke, Xiaoping
    Lin, Zhimiao
    EUROPEAN JOURNAL OF DERMATOLOGY, 2024, 34 (03) : 287 - 293
  • [33] Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
    Asati, Vivek
    Bharti, Sanjay K.
    Mahapatra, Debarshi Kar
    Asati, Vikas
    Budhwani, Ashok K.
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (39) : 6039 - 6054
  • [34] Co-alterations in PIK3CA and ARID1A lead to enhanced sensitivity to PI3K inhibition
    Udgata, Shirsa
    Stoecker, Jordan N.
    Lippert, Anna L.
    Pasch, Cheri A.
    Deming, Dustin A.
    CANCER RESEARCH, 2024, 84 (06)
  • [35] PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation
    Songlin Liu
    Yunhong Tang
    Maomao Yan
    Weixi Jiang
    Investigational New Drugs, 2018, 36 : 763 - 772
  • [36] PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation
    Liu, Songlin
    Tang, Yunhong
    Yan, Maomao
    Jiang, Weixi
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 763 - 772
  • [37] MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
    Fricke, Stephanie L.
    Payne, Susan N.
    Favreau, Peter F.
    Kratz, Jeremy D.
    Pasch, Cheri A.
    Foley, Tyler M.
    Yueh, Alexander E.
    Van De Hey, Dana R.
    Depke, Mitchell G.
    Korkos, Demetra P.
    Sha, Gioia Chengcheng
    DeStefanis, Rebecca A.
    Clipson, Linda
    Burkard, Mark E.
    Lemmon, Kayla K.
    Parsons, Benjamin M.
    Kenny, Paraic A.
    Matkowskyj, Kristina A.
    Newton, Michael A.
    Skala, Melissa C.
    Deming, Dustin A.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (02) : 346 - 355
  • [38] Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
    Vasan, N.
    Razavi, P.
    Johnson, J. L.
    Shao, H.
    Reznik, E.
    Smith, M. L.
    Sebra, R.
    Cantley, L. C.
    Scaltriti, M.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 1 - 1
  • [39] Targeting glutamine metabolism in PIK3CA mutant colorectal cancers
    Feng, Xiujing
    Hao, Yujun
    Wang, Zhenghe
    GENES & DISEASES, 2016, 3 (04) : 241 - 243
  • [40] Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
    Roper, Jatin
    Sinnamon, Mark J.
    Coffee, Erin M.
    Belmont, Peter
    Keung, Lily
    Georgeon-Richard, Larissa
    Wang, Wei Vivian
    Faber, Anthony C.
    Yun, Jihye
    Yilmaz, Oemer H.
    Bronson, Roderick T.
    Martin, Eric S.
    Tsichlis, Philip N.
    Hung, Kenneth E.
    CANCER LETTERS, 2014, 347 (02) : 204 - 211
12345